Lilly Reports Strong First-Quarter 20... (total revenue of $94.1 million for Erbit...)

Lilly Reports Strong First-Quarter 2009 Results

Date:4/20/2009

total revenue of $94.1 million for Erbitux, comprised of collaboration revenue of $68.0 million and product sales of $26.1 million.

Animal Health

Worldwide sales of animal health products in the first quarter of 2009 were $264.1 million, an increase of 12 percent compared with the first quarter of 2008. U.S. sales grew 43 percent, to $153.6 million, primarily due to the inclusion of sales from the Posilac(R) acquisition completed in October, 2008. Sales outside the U.S. decreased 13 percent, to $110.5 million, driven primarily by the unfavorable impact of exchange rates.

2009 Financial Guidance

The company reconfirmed its 2009 financial guidance, including its earnings per share guidance range of $4.00 to $4.25.

2009 Earnings Per Share Expectations:

2009 2008
Expectations Results % Growth
--------------- --------- ----------
Earnings (Loss) per share $4.00 to $4.25 ($1.89) NM
(reported)
Financial impact of ImClone
acquisition, including
in-process research and
development and other charges - 4.46
Charges related to Zyprexa
investigations - 1.20
Asset impairments and
restructuring charges
(included in asset
impairments, restructuring
and other special charges) - .30
Asset impairments (included in
cost of sales) - .04
In-process research and
development charges
associated with SGX
acquisition and in-licensing
transactions with BioMS and
TransPharma - .10
Benefit from resolution of IRS

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients

Post Your Comments:

Lilly Reports Strong First-Quarter 20...(total revenue of $94.1 million for Erbit...),Health